Compare Progressive Corp (PGR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs TransMedics Group Inc — how do they compare? Progressive Corp trades at $217.5 (market cap $126.95B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Progressive Corp is far larger — about 46.3× TransMedics Group Inc's market cap, and Progressive Corp pays a 0.18% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and TransMedics Group Inc for 24 Days on average.
| PGR | TMDX | |
|---|---|---|
Market Cap | $126.95B | $2.74B |
Volume | 2,749,438 | 949,331 |
Sector | Financials | Health |
52-Week High | $242.16 | $150.42 |
52-Week Low | $190.40 | $61.99 |
Typical Hold Time | 81 Days | 24 Days |
Enterprise Value | $135.16B | $3.13B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $218.51, up 2.05% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with 12.85% net income margin and 34.94% ROE, supported by consistent revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q2 2026 with EPS of $4.85 versus $4.64 expected, though Q1 2026 slightly missed. Analyst consensus price target is $222.23 with 38.1% buy ratings.
PGR presents a favorable risk-reward profile with upside to consensus targets, though near-term overbought RSI conditions warrant caution. The insurance giant's telematics advantage and underwriting discipline provide competitive moat, while intensifying auto insurance competition represents the primary business risk. Current valuation at 10.97 P/E appears reasonable given growth trajectory and profitability metrics.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
